Company
Marinus
NASDAQ:MRNS
Marinus Pharmaceuticals is a clinical stage biopharmaceutical company. The Company focuses on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, which is an endogenous neurosteriod known for its anticonvulsive and antianxiety activity.
6 stories
Marinus Pharmaceuticals Inc issues bullish report on anti-epileptic drug ganaxolone
Data suggests Marinus's drug ganaxolone is effective in treating certain forms of pediatric epilepsy
Marinus Pharmaceuticals sees shares slide on bigger-than-expected loss for 2017
But the developer of therapeutics to treat epilepsy said its cash position will enable it to fund its "current scale of operating expenses and capital expenditure requirements into 2020"
US benchmarks mixed heading into close
A look at US markets and the main Canada index throughout the day in New York
Marinus Pharmaceuticals shares surge on Nasdaq on successful clinical trial results
The candidate is being used to treat CDKL5 - a rare genetic disorder
Marinus completes patient recruitment in late stage trial of ganaxolone in focal onset seizures
The biopharmaceutical company expects top-line results from the study in mid-2016.